Helus Pharma (formerly Cybin Inc.) shares have dropped more than 50% following the unexpected departure of CEO Michael Cola in April 2026. Co-founder and Executive Chairman Eric So has assumed the role of interim CEO.
The company is awaiting topline data from its Phase 3 trial for HLP003, a treatment for major depressive disorder. These clinical results are expected in the fourth quarter of 2026.
Investors are currently weighing leadership instability against the potential of the upcoming trial data.